The improved efficacy of a biologic drug in combination with a conventional treatment in rheumatoid arthritis (RA) has been well demonstrated, but some biologic-naive patients are unable to tolerate drugs such as methotrexate. Limited data are available about which biologic to select for monotherapy in such patients, however.
The improved efficacy of a biologic drug in combination with a conventional treatment in rheumatoid arthritis (RA) has been well demonstrated, but some biologic-naive patients are unable to tolerate drugs such as methotrexate. Limited data are available about which biologic to select for monotherapy in such patients, however.
A recently published analysis, appearing in BMJ Open, used data from the Administrative Healthcare Database of Italy’s Lombardy region, as part of the RECord-linkage On Rheumatic Diseases (RECORD) study, to comparatively evaluate the persistence of treatment on different biologics used in monotherapy compared with combination therapy.
Click to read more about monotherapy for rheumatoid arthritis.
Patients with RA in the RECORD study were assessed to identify 799 patients who had at least 1 delivery of a first-line biologic as monotherapy, and 3679 patients who received combination therapy in the first line. Biologics used included abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, and tocilizumab. Rituximab was excluded due to local limitations on use. Monotherapy was associated with longer disease duration, hepatic and renal disease, heart failure, lower use of steroids, and lower use of nonsteroidal anti-inflammatory drugs.
Combination therapy has been shown in many studies to be associated with a 21% lower risk of drug failure, but among those who received monotherapy, considering etanercept as a reference point, the adjusted hazard ratio [HR] for biologic failure was 1.28 for adalimumab (95% CI, 1.03-1.59) and 2.41 for infliximab (95% CI, 1.85-3.15). Abatacept was associated with a reduced through not statistically significant risk of failure, and tocilizumab was approximately equal with etanercept. Among combination therapies, only infliximab was statistically inferior to etanercept monotherapy.
The authors of the analysis write that, while monotherapy is commonly observed, it is important to better understand the factors that drive monotherapy, such as comorbidities, body mass index, and higher disease activity.
The authors conclude that using biologics with conventional therapy is preferable to monotherapy, and further state that etanercept monotherapy should be preferred to infliximab and adalimumab when first-line monotherapy is necessary.
Reference
Silvagni E, Bortoluzzi A, Carrara G. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. BMJ Open.2018;8(9):e021447. doi: 10.1136/bmjopen-2017-021447.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.